

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/634740-Conf. #8302
		Filing Date	August 5, 2003
		First Named Inventor	Alice Y. Ting
		Art Unit	1653
		Examiner Name	R. B. Mondesi
Total Number of Pages in This Submission		Attorney Docket Number	
		M0656.70097US00	

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Part B - Fee(s) Transmittal; Supplemental Application Data Sheet; Telephone Interview Summary; Check in the amount of \$1,700.00; Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Maria A. Trevisan		
Date	March 21, 2006	Reg. No.	48,207

03.12.2006

Certificate of Express Mailing Under 37 CFR 1.10

Express Mail Label No. EV717202108US Dated: March 21, 2006



Docket No.: M0656.70097US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alice Y. Ting
Serial No.: 10/634740
Confirmation No.: 8302
Filed: August 5, 2003
For: GENETICALLY ENCODED FLUORESCENT REPORTERS OF KINASE, METHYL-TRANSFERASE, AND ACETYL-TRANSFERASE ACTIVITIES
Examiner: R. B. Mondesi
Art Unit: 1653

Certificate of Express Mailing Under 37 CFR 1.10

Express Mail Label No. EV717202108US Dated: March 21, 2006

TELEPHONE INTERVIEW SUMMARY

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant provides herewith a summary of the telephone interview with Examiner Mondesi conducted on March 16, 2006 and initiated by Applicant's representative. Applicant thanks the Examiner for the courtesy of this interview. During the interview, the parties discussed the status of the cancelled claims, and in particular cancelled claim 33, in view of the original restriction requirement. Applicant's representative indicated that the sequence of claim 33 was not part of the original restriction requirement mailed on November 17, 2004 which required an election from the sequences in claims 37-39. The sequence of claim 33 was not included in that restriction requirement. As a result, it has been Applicant's understanding during prosecution that the sequence of claim 33 would be considered and rejoined upon allowance of the generic claim. Applicant further noted that the sequences of claims 37-39 are histone peptides while the sequence of claim 33 is a bromodomain peptide. The disparate nature of these sequences is further evidence of their improper grouping by the Examiner. In response, the Examiner maintained that the restriction was proper.

Notwithstanding the above, Applicant notes the generic nature of claims 21, 132, 133 and 134 as allowed.

Respectfully submitted,



Maria A. Trevisan, Reg. No. 48,207
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
(617) 646-8000

Date: March 21, 2006
x03.21.2006